FDA Clears NinePoint’s Volumetric OCT System
Medical device manufacturer NinePoint Medical Inc. has received FDA 510 (k) clearance for its volumetric optical coherence tomography (OCT) imaging system.
Medical device manufacturer NinePoint Medical Inc. has received FDA 510 (k) clearance for its volumetric optical coherence tomography (OCT) imaging system.
NinePoint’s Nvision VLE Imaging System is a tool for the evaluation of human tissue microstructure by providing 2-D, cross-sectional, real-time depth visualization, according to the company. It is the first volumetric OCT device cleared by the FDA for endoscopic imaging that uses a circumferential scanning technique and an automated pullback to generate cross-sectional and longitudinal images simultaneously in real-time, the company said.
The system can image under the mucosal surface at less than 10 micros resolution up to a tissue depth of 3mm, and can image circumferentially or helically up to 6cm in length in less than 100 seconds, the company said.
“The Nvision VLE Imaging System can provide high-resolution images of potentially diseased tissue, which are deeper than can be imaged with endoscopy alone,” Charles Carignan, MD, president and CEO of NinePoint Medical, said in a statement.
“Our initial focus is on providing physicians with higher-resolution cross sectional and longitudinal images of diseased tissue in the epithelium of various organs, which impacts millions of adults in the United States.”
Carignan said the company will be conducting clinical trials of the Nvision VLE Imaging System in 2012 with plans of a commercial launch in 2013.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
